Heather Raymon is VP at Artiva Biotherapeutics, Inc. (ARTV). They have made 1 open-market trade across 1 company since 2026, most recently 2026-05-19.
CIK 0002028466
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ARTV | 148,228 | $868K |
Shares reported on the most recent Form 4, priced at the 2026-05-19 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARTV | SELL | 2026-05-19 | 2026-05-19 | $9.01 | $28K | -14.7% | +11.5% | +33.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.